You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

What is Jemperli:

JEMPERLI contains the active substance dostarlimab, which is a monoclonal antibody designed to recognise and attach to a specific target substance in the body.

JEMPERLI works by helping your immune system fight your cancer.

JEMPERLI is used in adults to treat a kind of cancer called endometrial cancer (cancer of the lining of the womb). It is given when cancer is first diagnosed, has spread or cannot be taken out by surgery, or has progressed on or following prior treatment.
JEMPERLI may be given in combination with other anticancer medicines.1

Safety Information

For safety information on Jemperli and potential side effects, please see the Jemperli Patient Information Leaflet (PIL).

It is important that you also read the package leaflets for the other anticancer medicines you may be receiving. If you have any questions about these medicines, ask your doctor.

View JEMPERLI Patient Information Leaflet (PIL)

This link will take you to www.medicines.ie which is a non-GSK website.

References:

  1. JEMPERLI Patient Information Leaflet (September 2025). Last accessed: January 2026.

JEMPERLI is a registered trademark of the GlaxoSmithKline group of companies

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting side effects you may get.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed on this website or in the product package leaflet. You can also report side effects directly to HPRA Pharmacovigilance on their website: www.hpra.ie. By reporting side effects, you can help provide more information on the safety of this medicine.